Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been assigned a consensus rating of “Hold” from the twenty-four analysts that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.65.

A number of research firms recently weighed in on ENDP. Piper Jaffray Companies reissued a “hold” rating and set a $7.00 price target on shares of Endo International in a research note on Friday, November 10th. Mizuho reissued a “buy” rating on shares of Endo International in a research note on Friday, November 10th. BMO Capital Markets dropped their price target on shares of Endo International from $11.00 to $10.00 and set a “market perform” rating for the company in a research note on Friday, November 10th. Cantor Fitzgerald dropped their price target on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Finally, Citigroup dropped their price target on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th.

Endo International (ENDP) traded up $0.22 on Monday, hitting $7.72. 3,410,902 shares of the company were exchanged, compared to its average volume of 7,116,117. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. The company has a market capitalization of $1,670.00, a P/E ratio of 1.55, a price-to-earnings-growth ratio of 2.04 and a beta of 0.59. Endo International has a twelve month low of $5.77 and a twelve month high of $17.99.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. The business had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. Endo International’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.01 earnings per share. equities analysts anticipate that Endo International will post 3.67 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Blair William & Co. IL acquired a new position in shares of Endo International in the second quarter valued at approximately $126,000. LMR Partners LLP acquired a new position in shares of Endo International in the third quarter valued at approximately $148,000. Point View Wealth Management Inc. boosted its holdings in shares of Endo International by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares during the period. Riverhead Capital Management LLC boosted its holdings in shares of Endo International by 64.4% in the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares during the period. Finally, Bank of Hawaii acquired a new position in shares of Endo International in the second quarter valued at approximately $180,000. Institutional investors own 93.17% of the company’s stock.

WARNING: “Endo International PLC (ENDP) Given Consensus Rating of “Hold” by Brokerages” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/endo-international-plc-endp-given-consensus-rating-of-hold-by-brokerages/1758099.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.